Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS)
详细信息 查看全文
- 作者：Yazhong Taoa ; 1 ; Xin Zhanga ; 1 ; Silva Markovic-Plesea ; b ; markovic@email.unc.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：TLR ; toll-like receptor ; IFN ; interferon ; RRMS ; relapsing-remitting multiple sclerosis ; IFNAR ; IFN receptor ; HC ; healthy control ; LOX ; loxorubin ; CNS ; central nervous system ; EAE ; experimental autoimmune encephalomyelitis ; Treg ; T regulatory cells ; Breg ; B regulatory cells ; DCs ; dendritic cells ; BCR ; B cell receptor ; PBMCs ; peripheral blood mononuclear cells ; SN ; supernatant ; FLUD ; fludarabine ; IRF ; interferon regulatory factor ; MOG ; myelin oligodendrocyte glycoprotein
- 刊名：Journal of Neuroimmunology
- 出版年：2016
- 出版时间：15 September 2016
- 年：2016
- 卷：298
- 期：Complete
- 页码：181-188
- 全文大小：940 K
文摘
- •
B cells from RRMS patients exhibit decreased IFNβ secretion and signaling.
- •
10">TLR7/TLR9 stimulation with exogenous IFNβ reconstitutes endogenous IFNβ expression.
- •
15">This combination therapy induces secretion of immunoregulatory cytokines in B cells.
- •
TLR7/9 agonists with IFNβ inhibit CD4+ cells' secretion of inflammatory cytokines.
- •
TLR7/9 agonists may enhance IFNβ's therapeutic effect in patients with RRMS.